Biomarker Testing Patterns and Treatment Outcomes in Patients With Advanced Non-Small Cell Lung Cancer and MET Exon 14 Skipping Mutations: A Descriptive Analysis From the US
Pharmacology, Toxicology and Pharmaceutical Science
3
17%
Biochemistry, Genetics and Molecular Biology
3
17%
Immunology and Microbiology
1
6%
Unspecified
1
6%
Other
0
0%
Unknown
5
28%
Attention Score in Context
Attention Score in Context
This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 25 May 2022.
All research outputs
#7,439,673
of 26,192,167 outputs
Outputs from Frontiers in oncology
#2,550
of 22,929 outputs
Outputs of similar age
#145,216
of 457,131 outputs
Outputs of similar age from Frontiers in oncology
#174
of 1,566 outputs
Altmetric has tracked 26,192,167 research outputs across all sources so far. This one has received more attention than most of these and is in the 71st percentile.
So far Altmetric has tracked 22,929 research outputs from this source. They receive a mean Attention Score of 3.1. This one has done well, scoring higher than 88% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 457,131 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 67% of its contemporaries.
We're also able to compare this research output to 1,566 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 88% of its contemporaries.
